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University Hospital Geneva. Department of Infectious Diseases,
24, Rue Micheli-du-Crest, CH-1211 Geneva 4, Switzerland
The in-vitro activity of five new fluoroquinolones, WIN 57273, sparfloxacin, flerox-
acin, temafloxacin and ciprofloxacin was determined against 543 recent clinical
isolates and eight quinolone resistant strains derived by mutation and their five
parent strains. WIN 57273 was the most active compound against Gram-positive
bacteria, sparfloxacin had a broad spectrum which was similar to that of cipro-
floxacin. Ciprofloxacin showed the greatest activity against Gram-negative bacteria.
Temafloxacin showing some activity against Gram-positive organisms and
Acinetobacter spp. Fleroxacin was the least active compound studied. Compared to
wild type parent strains, the mutated strains produced the following results. In
Enterobacter cloacae OmpF deficiency increased the MICs of all quinolones by
8-32-fold. In Pseudomonas aeruginosa OmpF deficiency had a limited effect, Omp
D2 deficiency combined with an increased lipopolysaccharide content produced
greater resistance, i.e. 4-16-fold; mutations in gyrase were associated with variously
increased MICs, depending on the strain and compound tested.
Introduction
Many new quinolone antimicrobial agents have been described recently, some of which
may reach clinical use. Ciprofloxacin is the most widely available quinolone with good
activity against Gram-negative bacteria (Wolfson & Hooper, 1989). The development
of newer quinolones has aimed to produce compounds with better activity against
Gram-positive and anaerobic bacteria (for example WIN 57273 and sparfloxacin) or
improved pharmacokinetic properties (fleroxacin and temafloxacin). WIN 57273
[l-cyclopropyl-7-(2,6-di-methyl^pyridmyl)-6-fluorc>-l,4-dihydro-4-oxo3-quinolinecar-
boxylic acid] benefits from a 1-cyclopropyl group at position 7 of the quinolone ring
and confers better activity against Gram-positive bacteria (Sedlock et a!., 1990).
Sparfloxacin (AT-4140 or RP 64206) [5-amino-l-cyclopropyl-6.8-difluoro-1.4-dihydro-
7(ch-3,5-dimethyl-l-piperazinyl)-4-oxoquinolone-3-carboxylic acid] is another new
promising quinolone (Nakamura et al.y 1989; Cooper et al., 1990).
The in-vitro activity of these new compounds has been compared to older quinolones
and other antimicrobial agents (Paganoni et al., 1988; Nakamura et al., 1989; Cooper
et al., 1990; Sedlock et al., 1990). In the present study we have directly compared
ciprofloxacin to four newer quinolones using 543 recent clinical isolates to produce an
indication of their relative merits in in-vitro tests. We also determined their activity
against strains with known mechanisms of resistance to quinolones.
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Materials and methods
Bacterial strains and antimicrobials used
A total of 556 bacterial strains were studied of which 543 were recently isolated at the
University Hospital of Geneva. The 21 isolates of Enterobactcriaceae (12 Escherichia
coli, 7 KJebsiella pneumoniae and 2 Enterobacter cloacae) resistant to nalidixic acid
(MIC > 16 mg/L) were evaluated separately. Eight strains in which the mechanism of
resistance to quinolones have been described were also studied (Michea-Hampzehpour
et al., 1987; Woodruff & Hancock, 1988; Lucain et al., 1989; Michea-Hampzehpour,
Lucain & Pechere, 1991). The five E. cloacae mutant strains were obtained from a
murine model of peritonitis after pefloxacin treatment. They were characterized by
outer membrane protein (Omp) F deficiency, as shown by outer membrane electro-
phoresis and by reduced uptake of [l4C]pefloxacin. In addition to the altered perme-
ability, partially purified DNA gyrase from three of the five strains showed a 100- to
450-fold 50% inhibitory concentration increase of pefloxacin as determined by a
supercoiling assay (Lucain et al., 1989). Pseudomonas aeruginosa H636 is a OmpF
deficient mutant after in-vitro insertion mutagenesis of the cloned Omp F gene, kindly
provided by W. A. Woodruff, Vancouver, Canada (Woodruff & Hancock, 1988).
P. aeruginosa 305 PT1 and PT2 were obtained in mice after pefloxacin therapy
(Michea-Hampzehpour et al., 1991). The post-therapy isolate PT1 was characterized
by the absence of Omp D2 on Western (immuno) blotting, decreased [l4C]pefloxacin
uptake, altered lipopolysaccharide pattern and increased 3-deoxy-D-mannooctulosonic
acid (KDO) concentration in the outer membrane. The post-therapy strain PT2 had an
unchanged outer membrane but displayed altered DNA gyrase, determined indirectly
by pefloxacjn inhibition of the p-^adenine incorporation.
Laboratory standards with known potency of the antimicrobials used were supplied
as follows: WIN 57273 by Sterling Drug Inc. USA, sparfloxacin by Rhdne-Poulenc
Sante, France, fleroxadn by Hofiman-La Roche, Switzerland, tcmafloxacin by Abbott,
USA and ciprofloxacin by Bayer AG, Germany.
Susceptibility tests
Minimum inhibitory concentrations (MICs) of the five compounds were determined by
an agar-dilution method (National Committee for Clinical Laboratory Standards,
1990). The medium used was Mueller-Hinton agar (Oxoid, Basingstoke, UK), but for
testing Proteeae 1-3% agar was added and for fastidious organisms it was supple-
mented with 5% lysed horse blood and Isovitalex at the manufacturers recommended
concentration (Bio-Merieux, France). A multipoint-inoculator (Cathra systems, MCT
Medical, Minnesota, USA) delivering 1 pL per spot was used to inoculate these plates
with 104 cfu. All plates were incubated at 35°C for 18-20 h. An incubation atmosphere
of air with 5% CO2 was used for Haemophilus spp. and Neisseria spp. The MIC was
determined as the lowest concentration of an agent which completely inhibited growth
disregarding a single colony or a faint haze of growth.
Results
The comparative activity of the five quinolone agents against 543 recent clinical isolates
is shown in Table I. Ciprofloxacin was the most active agent against Gram-negative
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Table I. Comparative MICs of five quinolone agents for recent clinical isolates of bacteria, the
number of isolates tested is shown in parentheses
Bacterium
E. coli (30)
Salmonella spp. (25)
Klebsiella spp. (45)
(30 K. pneumoniae,
15 K. oxytoca)
Enterobacter spp. (30)
(24 E. doaceae.
6 E. aerogenes)
P. mirabilis (25)
Indole +ve Proteus spp. (21)
(13 P. vulgaris,
8 Morganella morgantt)
Nalidixic acid
resistant Enterobacteriaceae
(12 E. coli, 7 K. pneumoniae,
2 E. cloacae)
Acinetobacter spp. (28)
P. aeruginosa (32)
Agent
WIN 57273
sparfloxacin
fleroxacin
temafloxacin
ciprofloxacin
WIN 57273
sparfloxacin
fleroxacin
temafloxacin
ciprofloxacin
WIN 57273
sparfloxacin
fleroxacin
temafloxacin
ciprofloxacin
WIN 57273
sparfloxacin
fleroxacin
temafloxacin
ciprofloxacin
WIN 57273
sparfloxacin
fleroxacin
temafloxacin
ciprofloxacin
WIN 57273
sparfloxacin
fleroxacin
temafloxacin
ciprofloxacin
WIN 57273
sparfloxacin
fleroxacin
temafloxacin
ciprofloxacin
WIN 57273
sparfloxacin
fleroxacin
temafloxacin
ciprofloxacin
WIN 57273
sparfloxacin
fleroxacin
temafloxacin
ciprofloxacin
MIC
Range
0O3-0-5
0008-003
O06-O25
003-0-12
0008-003
0-12-1
0015-006
0-12-0-25
0O6-0-12
0015-003
0-12-1
0015-0-25
006-0-5
0O3-0-25
0008-0-12
0-12-1
0O15-0-25
003-1
003-0-5
0O08-0-12
0-25-1
0-25-1
0-12-0-5
0-25-1
003-0-12
0-12-2
003-1
0O6-0-5
0O6-2
0015-0-12
0-5-> 32
O-12->32
0-5->64
O-12->32
O-12->32
003-0-5
0O08-0-25
0-12-2
0O3-0-5
0O3-0-5
1-32
0-5-32
1-64
0-5-32
0-12-8
(mg/L)
MIC*
0-12
0015
0-12
006
0015
0-5
006
0-12
0-12
003
1
006
0-12
0-12
003
0-5
003
012
006
0015
0-5
05
025
1
006
1
05
012
05
003
8
4
2
2
1
012
006
05
012
O12
2
1
2
2
025
MIQo
012
0015
012
006
0015
1
006
025
012
003
1
006
025
025
003
1
006
012
012
O03
1
05
05
1
006
1
1
012
1
006
>32
16
64
16
16
025
012
2
025
05
16
8
8
8
2
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Table I—continued
Bacterium Agent
MIC (mg/L)
Range MIC*, MIC*
X. maltophilia (14)
H. influenzae (26)
Neisseria meningitidis (29)
Moraxella catarrhalis (17)
Methicillin-susceptible
S. aweus (20)
Methicillin-resistant
S. aweus (21)
Coagulase-negative
Staphylococcus spp. (21)
S. pyogenes (22)
S. agalactiae (22)
WIN 57273
sparfloxacin
fleroxacin
temafloxacin
ciprofloxacin
WIN 57273
sparfloxacin
fleroxacin
temafloxacin
ciprofloxacin
WIN 57273
sparfloxacin
fleroxacin
temafloxacin
ciprofloxacin
WIN 57273
sparfloxacin
fleroxacin
temafloxacin
ciprofloxacin
WIN 57273
sparfloxacin
fleroxacin
temafloxacin
ciprofloxacin
WIN 57273
sparfloxacin
fleroxacin
temafloxacin
ciprofloxacin
WIN 57273
sparfloxacin
fleroxacin
temafloxacin
ciprofloxacin
WIN 57273
sparfloxacin
fleroxacin
temafloxacin
ciprofloxacin
WIN 57273
sparfloxacin
fleroxacin
temafloxacin
ciprofloxacin
05-^*
025-2
2-16
05-8
1-16
<O004-OO08
<O004-0O08
0015-006
0008-012
0008-003
<O004-0O08
<O004-0O08
O03
0008-003
<0O04-0O08
0008-003
0015-003
025
O06-O12
003-006
<O008-O015
0015-006
025-05
O12-O25
006-05
<0O08-0O15
0O15-O-12
05-1
025-05
012-05
< 0008-003
006-0-25
05-8
025-2
006-1
006-025
025-05
2-16
1-4
025-1
012-025
025-05
1-16
05-2
05-2
1
1
4
4
2
<0O04
SJO004
006
0015
0015
<0O04
<0O04
003
0015
<SO004
0015
0O3
025
006
006
<0O08
003
0 5
025
025
<*OO08
003
0 5
025
O25
<O008
012
0 5
012
012
012
0 5
8
1
1
012
0 5
8
1
1
4
1
8
8
8
4JO004
si 0004
006
006
003
<0004
O008
003
0015
<0004
0015
003
025
012
006
0015
006
05
025
025
<£O008
006
05
025
05
O015
012
1
025
012
025
05
16
2
1
012
05
8
1
1
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Bacterium Agent
MIC(mg/L)
Range MIC,, MIC*,
S. pneumoniae (22)
E.faecalis(2&)
E.faedum (22)
L. monocytogenes (22)
WIN 57273
sparfloxacin
fleroxacin
temafloxacin
ciprofloxacin
WIN 57273
sparfloxacin
fleroxacin
temafloxacin
ciprofloxacin
WIN 57273
sparfloxacin
fleroxacin
temafloxacin
ciprofloxacin
WIN 57273
sparfloxacin
fleroxacin
temafloxacin
ciprofloxacin
(H)3-O-12
006-O5
1-16
0-5-4
0-5-2
0O3-8
0-25-4
2-16
0-5-8
0-25-8
0-12-8
0-5-^ 4
4-16
1-16
1-8
0-12-0-25
1-2
2-16
0-5-8
0-5-2
006
0-25
4
1
1
0-12
0-5
8
2
1
4
2
8
4
4
0-12
2
8
2
1
006
0-25
8
2
2
2
2
8
4
4
8
4
16
8
4
0-25
2
8
2
1
bacteria, with the exception of Acinetobacter spp. and Xanthomonas maltophilia when
sparfloxacin was more active and Moraxella catarrhalis when WIN 57273 was four-fold
and sparfloxacin was two-fold more active than ciprofloxacin. Against
Enterobacteriaceae, (excluding Proteus spp.), a one- to four-fold increase in activity
was noted, the agents in order of increasing activity being WIN 57273, fleroxacin,
temafloxacin, sparfloxacin and ciprofloxacin. When a group of 21 nalidixic acid
resistant isolates of Enterobacteriaceae were examined, a similar increase in MIC was
observed for all the quinolones tested compared to the nalidixic acid sensitive species
(^-to 210-fold increased MICa or MIC^). All the agents tested with the exception of
ciprofloxacin, showed poor activity against Proteus mirabilis. Ciprofloxacin and flerox-
acin were the most active against the indole positive Proteus spp. being > 4-fold more
active than the other agents.
The most active compound against Gram-positive bacteria was WIN 57273 followed
by sparfloxacin, ciprofloxacin, temafloxacin and fleroxacin. Interestingly sparfloxacin
was twice as active against Staphylococcus aureus than coagulase-negative
Staphylococcus spp. in contrast to ciprofloxacin which was 2 times less active in this
context. Against Streptococcus spp. and Enterococcus spp. good activity for WIN 57273
and sparfloxacin was observed, but relatively high MICs of fleroxacin, temafloxacin
and ciprofloxacin were noted. All the quinolones tested had poor activity against
Enterococcus faecium; against Listeria monocytogenes only WIN 57273 had good
activity.
Table II shows the activity of quinolones against various mutants with known
mechanisms of resistance to quinolones. OmpF deficiency in E. cloacae was associated
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TaWe IL MICs of WIN 57273 (WIN), sparfloxacin (SPX), fleroxacin (FIX), temafloxacin
(TEM) and ciprofloxacin (CIP) for bacterial strains with known mechanisms of resistance and
MIC increase in 191C compared to the parent strain
Strain (alteration)
E. cloacae 218 PT1
(OmpF deficient)
E. cloacae 908 PT1
(OmpF deficient)
E. cloacae 218 PT2
(OmpF deficient+gyf")
E. cloacae 219 PT1
(OmpF deficient + gyr)
E. cloacae 908 PT2
(OmpF deficient + gyr)
P. aeruginosa H 636
(OmpF deficient)
P. aeruginosa 305 PT1
(Perm*)
P. aeruginosa 305 PT2
(gyr)
WIN
4
2
32
16
64
16
16
16
MIC (mg/L)
SPX
1
1
8
1
8
2
16
4
FLX
1
1
32
4
16
4
8
8
TEM
2
1
16
4
16
4
8
4
CIP
0-25
0-25
8
0-5
2
1
2
0-5
WIN
23
2}
2*
2*
21
22
23
23
MIC increase
SPX
2*
2J
2*
23
2*
2°
22
2°
FLX
2s
23
21
2*
27
21
2J
22
TEM
2*
23
27
25
27
2°
22
21
CIP
2*
r
2»
25
2'
2°
2<
22
•Altered DNA gyrase.
'Altered permeability due to the combination of decreased expression of OmP D2 and increased
production of Hpopolysaccharides.
with an 8- to 32-fold increase in MICs with parallel changes seen with all the
compounds. The OmpF deficient mutants which also possessed an altered DNA gyrase
showed variation in susceptibility to quinolones from strain to strain. The strains of
E. cloacae 219 PT1 and 908 PT2 were more susceptible to ciprofloxacin than
WIN 57273; the opposite was noticed for strain E. cloacae 218 PT2. In strains of
P. aeruginosa, OmpF deficiency had a limited effect on quinolone activity. Altered
permeability due to the combination of decreased expression of Omp D2 and increased
production of lipo-polysaccharide influence the activity of all quinolones by 4- to 16-
fold changes in MIC. Alteration of the P. aeruginosa gyrase produced effects depending
on the agent, sparfloxacin showing no changes whereas WIN 57273 showed an eight-
fold increase in MIC.
Discussion
In this study we confirm that the development of new quinolones like sparfloxacin or
WIN 57273 has lead to an increased activity against Gram-positive bacteria when
compared to older agents. Our results, in which we made direct comparison of five
recently developed quinolones, are similar to those published by other investigators in a
different setting (Auckenthaler et al., 1986; Paganoni etal., 1988; Nakamura etal.,
1989; Cooper etal., 1990; Sedlock etal., 1990). WIN 57273 showed good activity
against Gram-positive bacteria, with the exception of E.faecium. Depending on its
pharmacological properties and toxicological profile, WIN 57273 could become a
useful agent to treat infections caused by Staphylococcus spp., Streptococcus spp. and
L. monocytogenes.
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Sparfloxacin was less active against Gram-positive bacteria than WIN 57273, but it
had a broader spectrum of activity, more like ciprofloxacin. The two- to four-fold
decrease in MIC of sparfloxacin compared to ciprofloxacin for Streptococcus pneu-
moniae could be an advantage in the treatment of community acquired respiratory
infections. The in-vitro activity of temafloxacin was interesting against quinolone
susceptible Gram-positive bacteria. Fleroxacin was the least active compound, but
these results should be interpreted in relation to its distinctive pharmacokinetic
properties. Comparing the results for ciprofloxacin to those we obtained in a study we
conducted five years ago (Auckenthaler et al., 1986), we noted similar MICs, even
though a completely different set of strains was tested. Only the MIC*, for Salmonella
spp. and P. mirabilis and the MIQo for P. aeruginosa, Haemophilus influenzae and
E.faecalis have increased four-fold, but that for Acinetobacter spp. has decreased by a
factor of 4.
As the nalidixic acid resistance rate for Enterobacteriaceae is lower than 5% in our
hospital, we separately listed a selection of these strains. The overall MIC values were
similarly increased for all quinolones compared to nalidixic acid susceptible
Enterobacteriaceae. However, differences for individual strains were noted.
In Gram-negative bacilli two mechanisms of quinolone resistance have been recog-
nized affecting the penetration through the outer membrane or the affinity to the target
molecule, DNA gyrase. Permeability mutants in E. cloacae are characterized by altered
outer membrane protein patterns, principally marked by a decreased 37 kDa band
(named OmpF in analogy to E. coli) accompanied by an increased 42 kDa band (i.e.
OmpC) (Lucain et al., 1989). In our study, strains possessing these changes showed a
moderate increase in resistance to all five agents. In order to evaluate the impact of
alteration of the DNA gyrase, as no strain only carrying a gyrase mutation was
available to us, we tested three strains having an altered gyrase combined with a
decreased permeability. These strains with two mechanisms of resistance showed
marked resistance to the quinolones tested. Furthermore we observed that MICs of
these quinolones were not equally altered. For two strains WIN 57273 was more
affected than ciprofloxacin, the opposite applied for the third strain. This opposite
trend remained also when subtracting the theoretical contribution of reduced perme-
ability. This suggests that various mutations of the DNA gyrase have different effects
on quinolone activity as has been shown in S. aureus (Hopewell et al., 1990).
Changes in the outer membrane of P. aeruginosa with altered permeability are
complex, with modified protein and lipopolysaccharide band patterns (Michea-
Hamzehpour et al., 1991). When we tested the OmpF deficient strain of P. aeruginosa
H 636, we observed only small changes in MIC. The role of Protein F as a porin in
P. aeruginosa has been controversial (Gotoh et al., 1989; Woodruff et al., 1988), but it
has been recently reported that it may function as a major non-specific porin for the
diffusion of hydrophilic solutes with limited permeability (Nikaido, Nikaido &
Harayama, 1991). According to our observations, the role of OmpF in quinolone
resistance remains doubtful. However, the contribution of this porin in quinolone
uptake cannot be definitely ruled out because the structure of the outer membrane is
greatly altered in OmpF deficient mutants (Woodruff et al., 1988). We also tested a
strain of P. aeruginosa with altered permeability due to reduced expression of Omp D2
combined with increased amount of lipopolysaccharides in the outer membrane. These
alterations more markedly reduced the activity of quinolones than did deficiency of
OmpF, which confirms our recent observation that both Omp D2 and
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lipo-polysaccharides are involved in the diffusion of quinolones through the outer
membrane (Michea-Hamzehpour et al., 1991). Interestingly, we observed that in a
P. aeruginosa strain with only a mutated DNA gyrase, similar changes in the MICs of
quinolones were seen as observed for E. cloacae.
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